Company intelligence / Profile preview
Viventia
Winnipeg, Manitoba, Canadaviventia.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Viventia's lead program, vicinium, advanced to Phase 3 for non-muscle invasive bladder cancer with promising preliminary efficacy. Proxinium, targeting head and neck cancers, entered Phase 2 and received orphan drug and Fast Track designations in the US and EU. The company had a broader preclinical pipeline including multiple targeted protein therapeutics using antibody fragment-fusion toxin constructs.[6]
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugateMonoclonal antibodyProtein
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Viventia.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Viventia.